检索结果-南通市图书馆

中国循证医学杂志 2007年第5期7卷 392-396页

作者： Lorenzo Moja Ivan Moschetti Alessandro Liberati roberto Manfrini Christian Deligant roberto satolli Antonio Addis Nello Martini Pietro Dri 陈耀龙（译）刁骧（审校）意大利Cochrane中心 Istituto Marlo Negri意大利米兰 Zadig科学出版公司意大利米兰意大利药物署（AIFA）意大利罗马不详

尽管循证医学（EBM）对卫生政策和临床实践的影响尚未确定，但在意大利，人们对循证医学的兴趣却与日俱增。意大利医生的信息需求很大程度上仍依赖于药厂，而非无偏倚的循证资源。例如，近期一项调查显示：全科医生每周会接受11次医药... 详细信息

尽管循证医学（EBM）对卫生政策和临床实践的影响尚未确定，但在意大利，人们对循证医学的兴趣却与日俱增。意大利医生的信息需求很大程度上仍依赖于药厂，而非无偏倚的循证资源。例如，近期一项调查显示：全科医生每周会接受11次医药代表的来访。该调查表明医生认为药厂提供的信息完整且可靠性较高。

关键词：继续医学教育循证医学临床证据

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

引用

World Journal of Clinical Oncology 2016年第1期7卷 27-43页

作者： Rosella Spadi Federica Brusa Agostino Ponzetti Isabella Chiappino Nadia Birocco Libero Ciuffreda Maria Antonietta satolli Department of Oncology Azienda Ospedaliera Città della Salute e della Scienza

Pancreatic cancer(PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in borderline resectable and locally advanced PC. Second line treatments showed to positively affect both overall survival and quality of life in fit patients affected by metastatic disease. At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, thus, current clinical practice does not include them. Up to now, despite the fact of extremely promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease.

关键词： Pancreatic cancer Chemotherapy Radiofrequency Stereotactic radiotherapy Irreversible electroporation

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Gastric cancer:The times they are a-changin'

引用

World Journal of Gastrointestinal Oncology 2015年第11期7卷 303-316页

作者： Maria Antonietta satolli Lucio Buffoni Rosella Spadi Ilaria Roato Department of Oncology University of Turin Department of Onco-ematology Medical OncologyAOU Città della Salute e della ScienzaMolinette10126 TurinItaly CeRMS AOU Città della Salute e della Scienza di TorinoDepartment of Medical ScienceUniversity of Turin

Gastric cancer is the third leading cause of cancer death *** though during these last decades gastric cancer incidence decreased in Western countries,it remains endemic and with a high incidence in Eastern *** survival in advanced and metastatic stage of gastric cancer is still very *** the Cancer Genoma Atlas Research Network identified four subtypes with different molecular profiles to classify gastric cancer in order to offer the optimal targeted therapies for pre-selected ***,the key point is still the selection of patients for the right treatment,on basis of molecular tumor *** chemotherapy reached a plateau of efficacy for gastric cancer,the combination between cytotoxic therapy and biological agents gets a better prognosis and decreases chemotherapeutic ***,Trastuzumab in combination with platinum and fluorouracil is the only approved targeted therapy in the first line for c-erb B2 positive patients,whereas Ramucirumab is the only approved targeted agent for patients with metastatic gastric *** perspectives for an effective treatment derived from the immunotherapeutic ***,we report an overview on gastric cancer treatments,with particular attention to recent advances in targeted therapies and in immunotherapeutic approach.

关键词： Targeted therapy Chemotherapy Gastric cancer Immun

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Advanced non-small cell lung cancer in elderly patients: A review

引用

World Journal of Respirology 2015年第2期5卷 102-111页

作者： Lucio Buffoni Lorena Consito Andrea Riccardo Filippi Enrico Ruffini Paolo Solidoro Paolo Bironzo Maria Antonietta satolli Marina Schena Libero Ciuffreda Department of Medical Oncology San Giovanni Battista Molinette Hospital Department of Oncology Radiation OncologyUniversity of Turin Department of Thoracic Surgery School of MedicineUniversity of Turin Division of Pulmonology University of Turin Department of Oncology University of Turin

Over 50% of patients diagnosed with non-smallcell lung cancer(NSCLC) are 65 years old while 30% exceed 70 years old. Comparing elderly patients to their younger counterpart they poorly tolerate chemotherapy due to progressive reduction of organ function and age-related co-existing pathologies. Due to this reason elderly are usually excluded from platinum-based chemotherapy, which still represent the standard of care for advanced NSCLC. In every-day practice, single-agent schedule with a third-generation drug is the recommended option for elderly patients with advanced NSCLC. A modest increase in toxicity for elderly patients has been demonstrated by subgroup analyses concluding for platinum-based combination chemotherapy being similar in young patients and fit elderly. Even though the cited evidence, feasibility of chemotherapy based on platinum remains an open question. Prospective randomised trials are warranted in order to change guide lines and give the clinicians a new therapeutic option. Recent emerging role of molecular target in selecting patients for new targeted therapies suggest dedicated trials for elderly patients. The same is for more accurate evaluation of elderly patients with increasing evidence for a comprehensive geriatric assessment as a valid tool for customized treatment in NSCLC elderly patients. Suitable evidences for the treatment of elderly patients affected by advanced NSCLC together with more appropriate and validated tools for patients selection are reviewed along the manuscript.

关键词： Lung cancer Elderly Chemotherapy Target therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：